Ignite Creation Date:
2024-05-05 @ 5:21 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00436800
Status:
COMPLETED
Last Update Posted:
2009-09-18
First Post:
2007-02-16
Brief Title:
Gemcitabine and Oxaliplatin GEMOX in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
Gemcitabine and Oxaliplatin in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma NPC
Status:
COMPLETED
Status Verified Date:
2009-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Primary objective
To evaluate the response rate of biweekly gemcitabine and oxaliplatin the GEMOX regimen in the first line treatment of metastatic or recurrent nasopharyngeal carcinoma
Secondary objectives
To assess the toxicity duration of response time to progression progression-free survival overall survival and cancer-related symptoms in the first line treatment of patients with metastatic or recurrent NPC
To evaluate the response rate of biweekly gemcitabine and oxaliplatin the GEMOX regimen in the first line treatment of metastatic or recurrent nasopharyngeal carcinoma
Secondary objectives
To assess the toxicity duration of response time to progression progression-free survival overall survival and cancer-related symptoms in the first line treatment of patients with metastatic or recurrent NPC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None